GlassScriptPhysician profile
David J Kardesch
NPI 1609875699
$3,659.32
in general payments reported to CMS, 2019-2025
28 companies · $601 in 2025
The $601 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $34.32 · 2021: $129 · 2022: $482 · 2023: $804 · 2024: $1,367 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,581 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,581.45 |
| Education | $191.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $464.62 | 2021-2025 | Optis, Jot Dx, Merlin@Home |
| Boston Scientific Corporation | $255.62 | 2021-2024 | Watchman Access System |
| Abiomed | $231.34 | 2021-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $219.54 | 2022-2024 | |
| Amgen INC. | $211.58 | 2020-2025 | Repatha, Repatha |
| Impulse Dynamics (USA) INC. | $194.56 | 2024 | Optimizer |
| Pfizer INC. | $190.55 | 2022-2025 | |
| Kestra Medical Technology Services, INC. | $184.79 | 2024-2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $177.33 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $173.89 | 2023-2025 | Farxiga, Brilinta, Wainua |
| Shockwave Medical, INC | $154.36 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cardiovascular Systems INC. | $152.69 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.67 | 2021-2025 | Lifevest |
| Edwards Lifesciences Corporation | $138.82 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novo Nordisk INC | $119.27 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $116.79 | 2022-2025 | Verquvo, Steglatro |
| Actelion Pharmaceuticals US, INC. | $105.56 | 2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $71.89 | 2020-2025 | Camzyos |
| Esperion Therapeutics, INC. | $61.45 | 2022-2023 | Nexletol |
| Biotronik INC. | $57.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.85 | 2023-2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $43.96 | 2024 | Arcalyst |
| Philips North America LLC | $38.10 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $22.31 | 2022 | |
| Glaxosmithkline, LLC. | $21.37 | 2025 | Arexvy |
| Chiesi USA, INC. | $17.80 | 2022 | |
| Medtronic, INC. | $17.23 | 2023 | Linq II |
| Convatec INC. | $16.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kardesch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.